Negrao Marcelo V - Heart Institute (InCor),, University of São Paulo Medical School

基本信息

浏览量：2

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 167 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer

Haniel A Araujo, Ximo Pechuan-Jorge,Teng Zhou,Minh Truong Do, Xin Hu,Frank R Rojas Alvarez, Maria E Salvatierra, Heladio P Ibarguen,Richard Lee, Rashi Raghulan,Harshit Shah, Mariela A Moreno Ayala,Kevin Chen,Nataliya Tovbis Shifrin,Shuhong Wu,Luisa M Solis Soto,Marcelo V Negrao,Don L Gibbons,David S Hong,Jack A Roth,John V Heymach,Jianjun Zhang,Jingjing Jiang,Mallika Singh,Jacqueline A M Smith,Elsa Quintana,Ferdinandos Skoulidis

Cancer discoveryno. 11 (2024): 2183-2208

引用0浏览0WOS引用

Safety and Intracranial Activity of Adagrasib in Patients with KRASG12C-Mutated Non-Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series

Ezra Bernstein,Jia Luo,Kaiwen Wang,Marcelo V. Negrao,Pasi A. Janne,Joshua K. Sabari

JCO PRECISION ONCOLOGY (2024)

引用0浏览0WOS引用

Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma with EGFR Germline Mutations

Kelsey Pan, Jennifer Owens,Yasir Elamin,Charles Lu,Mark Routbort,Jianjun Zhang,Frank Fossella,Marcelo V. Negrao,Mehmet Altan, Jenny Pozadzides,Ferdinandos Skoulidis,Anne Tsao,Tina Cascone,John Heymach,Edwin Ostrin,Xiuning Le

JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): 1438-1448

引用0浏览0WOS引用

Abstract 1935: The FAK/SRC axis mediates resistance to KRAS G12C inhibitors and its blockade can overcome KRAS inhibitor resistance

Yuji Shibata,Hibiki Udagawa,Monique B. Nilsson,Jacqulyne Robichaux,Ana Galan-Cobo,Marcelo Negrao,David P. Molkentine,Junqin He,Alissa Poteete,Yu Qian, Qian Huang,Ferdinandos Skoulidis,John V. Heymach

Cancer Researchno. 6_Supplement (2024): 1935-1935

引用0浏览0引用

Author Correction: BRAFV600E-mutant Metastatic NSCLC: Disease Overview and Treatment Landscape

David Planchard,Rachel E Sanborn,Marcelo V Negrao,Aria Vaishnavi,Egbert F Smit

npj precision oncology（2024）

引用0浏览0WOSNATURE引用

KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

P. Cassier,C. Dooms,A. Gazzah,E. Felip,N. Steeghs,K. S. Rohrberg,F. De Braud,B. Solomon,M. Schuler,D. S. Tan, N. Yamamoto,H. H. F. Loong,B. C. Cho,J. Wolf,C. C. Lin,M. V. Negrao, L. Werner, X. Cui,A. F. Farago,M. J. DeMiguel

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICSno. 1 (2024): E4-E5

引用0浏览0引用

16P A phase Ib/II trial to evaluate safety and efficacy of aurora kinase inhibitor LY3295668 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancer

X. Le,Y.Y. Elamin,M. Altan,G. Blumenschein,L.A. Byers,T. Cascone,F. Skoulidis,C. Gay,A.S. Tsao,D. Gibbons,M.V. Negrao,N. Vokes, J. Zhang,S. Heeke,J. Rotow,P.A. Jänne, B. Pellini,J. Tu, J.E. Gray,J. Heymach

ESMO Open (2024)

引用0浏览0引用

SUNRAY-01, a Pivotal, Global Study of Olomorasib (LY3537982) in Combination with Pembrolizumab with or Without Chemotherapy for 1L Treatment in KRAS G12C-mutant Advanced NSCLC

Marcelo Vailati Negrao,Kathryn C. Arbour,Timothy F. Burns,Federico Cappuzzo, Anne-Marie C. Dingemans,Nicolas Girard,Bjorn Henning Gronberg,Maximilian Hochmair,Ticiana Leal,Colin R. Lindsay,Shun Lu,Makoto Nishio, Luis G. Paz-Ares,Martin Reck,Joshua K. Sabari, Alexander I. Spira,William Nassib William, Aaron Chen,Carla M. Visseren Grul,Solange Peters

Journal of Clinical Oncologyno. 23_suppl (2024): TPS218-TPS218

引用0浏览0引用

1299P First-line Immunotherapy Versus BRAF and MEK Inhibitors for Patients with BRAF V600E Mutant Metastatic Non-Small Cell Lung Cancer

A. Di Federico, M.F. Chen, A. Pagliaro,F.R. Ogliari,P. Stockhammer, M. Aldea, M. Grant,A. De Giglio,J.V. Alessi,F. Pecci,F. Gelsomino,M.V. Negrao, R. Ferrara, M. Awad,G.J. Riely, A. Ardizzoni, D. Planchard, M.D. Offin, B.E. Johnson,B. Ricciuti

Annals of Oncology (2024)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn